-
Study aim
-
The main objective is to investigate the effectiveness of adding tDCS to resistance training on upper-limb QoL, performance, and movement smoothness in stroke patients.
-
Design
-
A clinical trial with a placebo-controlled parallel-group, double-blind, randomized design, using sealed opaque envelopes for randomization
-
Settings and conduct
-
Patients from neuro-rehabilitation clinics who meet the inclusion and exclusion criteria after signing informed consent will be allocated, using sealed, opaque envelopes, into two groups: resistance training placebo and resistance training with tDCS. Assessments will be performed by a physiotherapist blinded to treatment. It will be noted that tDCS sensation may be absent, but stimulation will be delivered, and patients will be blinded to group allocation. tDCS and therapeutic training will be performed by different therapists. The statistician will be blinded to group allocation, and the study will be double‑blind.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria
Age 45–75; Ischemic hemiplegia; Stroke in MCA territory; ≥3 months since event; Upper-limb 18–48 on Fugl-Meyer; Shoulder pain <3 on VAS; MAS score for biceps = 2; No cognitive/perceptual impairments preventing regimen (MMSE ≥18); Written informed consent approved for participation in the study
Exclusion criteria
Complex regional pain ; Depression preventing participation; CVD; Other neuro, ortho, rheumatological issues; Severe comorbid conditions; Contracture
-
Intervention groups
-
Resistance training with tDCS
Resistance training with tDCS in a placebo form
-
Main outcome variables
-
Fugl-Meyer Test ; Modified Ashworth Scale; Stroke Impact Scale ; Maximum muscle strength: flexors, extensors, adductors, abductors, and internal and external rotators of the shoulder; Maximum ROM for shoulder flexion and abduction; Kinematics : calculation of movement smoothness in flexion and abduction